Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from February 2020, including:
- A Federal Circuit decision applies a presumption that an express license to a patent includes an implied license to its continuations.
- A district court finds after trial that defendants’ obviousness theory had “major defects and does not come close to meeting the clear and convincing standard.”
- A district court holds that dedication-disclaimer does not apply where the allegedly dedicated subject matter is found in another claim in the same patent.
- The FDA and FTC announce a collaboration “to advance competition in the biologic marketplace.”
